Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nipro, Samsung Bioepis Tie Up on Biosimilar Business in Japan
June 10, 2025
- Sawai Follows Fuso to Challenge Remitch Patent Ruling
June 10, 2025
- Otsuka’s Sibeprenlimab Scores Positive Results in PIII: Interim Analysis
June 9, 2025
- Sumitomo Divests Canadian Business to Knight
June 9, 2025
- BMS Files Label Expansion of Sotyktu for Psoriatic Arthritis in Japan
June 9, 2025
- Tivdak Offers Valuable New Option as 2nd-Line Cervical Cancer Therapy: Oncologist
June 9, 2025
- Antibody Market to Reach 2.6 Trillion Yen in 2034: Fuji Keizai
June 9, 2025
- Moderna Files Updated Spikevax for LP.8.1 Strain in Japan
June 9, 2025
- Fuso Takes Remitch Patent Case to Top Court
June 9, 2025
- Japan Ethical Drug Sales Up 1.2% in April: Crecon
June 9, 2025
- Takeda Rolls Out AI Tool to Guide “Next Best Action” in Sales
June 6, 2025
- Meiji, Daito to Launch Talks on New Consortium to Stabilize Generic Supply, Boost Profitability
June 6, 2025
- Keytruda Japan’s Top-Selling Drug for 20th Month Running: Encise
June 6, 2025
- Santen’s Myopia Drug Approved in Europe
June 6, 2025
- Towa/CiRA to Launch PII/III Trial of Bromocriptine for Familial AD
June 5, 2025
- Fuji Keizai Issues 2040 Market Outlook for Dermatology, Collagen Diseases and More
June 5, 2025
- Takeda’s Adcetris Widens Label in Europe
June 5, 2025
- Enhertu Entering New Phase of Growth with Early-Line Breast Cancer Data: CEO
June 4, 2025
- Sawai Cuts FY2024 Results after Remitch Ruling, Net Profit Drops by Half
June 4, 2025
- Dupixent’s COPD Use Expected to Benefit Patients with Allergic Symptoms: Professor
June 3, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…